We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2005 by Hamamatsu University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00310739
First Posted: April 4, 2006
Last Update Posted: November 7, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hamamatsu University
  Purpose
We previously reported early measurement of urinary MDA might be a useful marker for the prediction of CDDP-induced renal damage in rat. The purpose of this clinical study is to test whether the changes of human urinary excretion of MDA, and can be used as early biomarker for the prediction of development of CDDP-induced ARF.

Condition
Kidney Failure

Study Type: Observational
Study Design: Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective

Further study details as provided by Hamamatsu University:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hospitalized patients have neck cancer
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00310739


Contacts
Contact: Takayuki Tsuji, MD +81-53-435-2261 tsu@hama-med.ac.jp

Locations
Japan
Hamamatsu University School of Medicine Recruiting
Hamamatsu, Shizuoka, Japan, 431-3192
Contact: Takayuki Tsuji, MD    +81-53-435-2261    tsu@hama-med.ac.jp   
Sponsors and Collaborators
Hamamatsu University
Investigators
Principal Investigator: Takayuki Tsuji, MD Hamamatsu University
  More Information

ClinicalTrials.gov Identifier: NCT00310739     History of Changes
Other Study ID Numbers: 16-50
First Submitted: April 3, 2006
First Posted: April 4, 2006
Last Update Posted: November 7, 2006
Last Verified: April 2005

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases